# Neuropace Inc. (NPCE)

Source: https://www.quantisnow.com/company/NPCE
Generated: 2026-11-09T20:00:57.630Z

- Ticker: NPCE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- IPO year: 2021
- SEC CIK: 0001528287
- Website: neuropace.com

## About

NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

## Latest NPCE news and filings

- 2026-10-29 20:05 UTC [Earnings Date] [NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026](https://www.quantisnow.com/insight/neuropace-to-report-third-quarter-2026-financial-results-on-november-6763409)
- 2026-09-25 20:31 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.65% to 51,357 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/chief-medical-officer-morrell-martha-covered-exercisetax-liability-with-335-6726609)
- 2026-09-21 20:56 UTC [SEC Form 4] [Chief Financial Officer Williams Patrick F. covered exercise/tax liability with 1,162 shares, decreasing direct ownership by 2% to 67,508 units (SEC Form 4) (tax liability)](https://www.quantisnow.com/insight/chief-financial-officer-williams-patrick-f-covered-exercisetax-liability-with-6721900)
- 2026-09-18 12:29 UTC [Analyst Coverage Initiated] [KeyBanc Capital Markets initiated coverage on NeuroPace with a new price target](https://www.quantisnow.com/insight/keybanc-capital-markets-initiated-coverage-on-neuropace-with-a-new-6720112)
- 2026-09-04 21:42 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,310 shares, decreasing direct ownership by 0.94% to 138,000 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-executive-officer-becker-joel-covered-exercisetax-liability-with-1310-6706857)
- 2026-09-01 21:01 UTC [Conference Announcement] [NeuroPace to Participate in 2026 Cantor Global Healthcare Conference](https://www.quantisnow.com/insight/neuropace-to-participate-in-2026-cantor-global-healthcare-conference-6701733)
- 2026-08-31 20:05 UTC [Conference Announcement] [NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference](https://www.quantisnow.com/insight/neuropace-to-participate-in-wells-fargo-21st-annual-healthcare-conference-6699687)
- 2026-08-28 21:04 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.80% to 139,310 units (SEC Form 4) to satisfy withholding obligation](https://www.quantisnow.com/insight/chief-executive-officer-becker-joel-covered-exercisetax-liability-with-1126-6698657)
- 2026-08-28 21:03 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.69% to 51,692 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/chief-medical-officer-morrell-martha-covered-exercisetax-liability-with-358-6698650)
- 2026-08-14 21:40 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-neuropace-inc-6683804)
- 2026-08-11 20:33 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neuropace Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neuropace-inc-6676190)
- 2026-08-11 20:07 UTC [SEC Form 8-K] [Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neuropace-inc-filed-sec-form-8-k-results-of-operations-and-6675762)
- 2026-08-11 20:05 UTC [Earnings Date] [NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance](https://www.quantisnow.com/insight/neuropace-reports-second-quarter-2026-financial-results-and-raises-2026-6675672)
- 2026-07-28 20:31 UTC [SEC Form 8-K] [Neuropace Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/neuropace-inc-filed-sec-form-8-k-regulation-fd-disclosure-6651738)
- 2026-07-28 20:01 UTC [Earnings Date] [NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy](https://www.quantisnow.com/insight/neuropace-receives-fda-guidance-on-pma-supplement-for-indication-expansion-6651277)
- 2026-07-23 12:24 UTC [Analyst Coverage Initiated] [Mizuho initiated coverage on NeuroPace with a new price target](https://www.quantisnow.com/insight/mizuho-initiated-coverage-on-neuropace-with-a-new-price-target-6646411)
- 2026-06-25 20:12 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 335 shares, decreasing direct ownership by 0.64% to 52,050 units (SEC Form 4) to satisfy withholding obligation](https://www.quantisnow.com/insight/chief-medical-officer-morrell-martha-covered-exercisetax-liability-with-335-6615835)
- 2026-06-22 20:34 UTC [SEC Form 4] [Director Geiger Uri was granted 789 shares, increasing direct ownership by 4% to 18,537 units (SEC Form 4)](https://www.quantisnow.com/insight/director-geiger-uri-was-granted-789-shares-increasing-direct-ownership-6610964)
- 2026-06-22 20:33 UTC [SEC Form 4] [Director Fischer Frank M was granted 1,467 shares, increasing direct ownership by 0.25% to 599,534 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fischer-frank-m-was-granted-1467-shares-increasing-direct-6610957)
- 2026-06-22 20:32 UTC [SEC Form 4] [Director Kumar Rakhi was granted 989 shares, increasing direct ownership by 4% to 23,039 units (SEC Form 4)](https://www.quantisnow.com/insight/director-kumar-rakhi-was-granted-989-shares-increasing-direct-ownership-6610948)
- 2026-06-08 20:54 UTC [SEC Form 8-K] [SEC Form 8-K filed by Neuropace Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-neuropace-inc-6593795)
- 2026-06-05 21:13 UTC [SEC Form 4] [Director Huennekens R Scott was granted 2,890 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-huennekens-r-scott-was-granted-2890-shares-sec-form-6591912)
- 2026-06-05 21:10 UTC [SEC Form 4] [Director Fischer Frank M was granted 2,890 shares, increasing direct ownership by 0.49% to 598,067 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fischer-frank-m-was-granted-2890-shares-increasing-direct-6591898)
- 2026-06-05 21:10 UTC [SEC Form 4] [Director Geiger Uri was granted 2,890 shares, increasing direct ownership by 19% to 17,748 units (SEC Form 4)](https://www.quantisnow.com/insight/director-geiger-uri-was-granted-2890-shares-increasing-direct-ownership-6591895)
- 2026-06-05 21:10 UTC [SEC Form 4] [Director Kumar Rakhi was granted 2,890 shares, increasing direct ownership by 15% to 22,050 units (SEC Form 4)](https://www.quantisnow.com/insight/director-kumar-rakhi-was-granted-2890-shares-increasing-direct-ownership-6591892)
- 2026-06-05 21:09 UTC [SEC Form 4] [Director Ryan Renee was granted 2,890 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-ryan-renee-was-granted-2890-shares-sec-form-4-6591878)
- 2026-06-05 21:09 UTC [SEC Form 4] [Director Andrade Lisa was granted 2,890 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-andrade-lisa-was-granted-2890-shares-sec-form-4-6591873)
- 2026-06-04 20:03 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,255 shares, decreasing direct ownership by 0.89% to 140,436 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-executive-officer-becker-joel-covered-exercisetax-liability-with-1255-6589199)
- 2026-05-29 12:05 UTC [NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting](https://www.quantisnow.com/insight/neuropace-to-highlight-expanding-role-of-responsive-neuromodulation-at-the-6578406)
- 2026-05-29 12:00 UTC [NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care](https://www.quantisnow.com/insight/neuropace-announces-fda-approval-of-ecog-assistant-advancing-ai-driven-epilepsy-6578364)
- 2026-05-28 20:42 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 0.79% to 141,691 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/chief-executive-officer-becker-joel-covered-exercisetax-liability-with-1126-6577570)
- 2026-05-28 20:40 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 358 shares, decreasing direct ownership by 0.68% to 52,385 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-medical-officer-morrell-martha-covered-exercisetax-liability-with-358-6577561)
- 2026-05-19 20:51 UTC [SEC Form 4] [Chief Financial Officer Williams Patrick F. was granted 16,820 shares, increasing direct ownership by 32% to 68,670 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-williams-patrick-f-was-granted-16820-shares-6563170)
- 2026-05-19 20:27 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER Morrell Martha was granted 5,460 shares, increasing direct ownership by 12% to 52,743 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-morrell-martha-was-granted-5460-shares-increasing-6562861)
- 2026-05-19 20:26 UTC [SEC Form 4] [CHIEF EXECUTIVE OFFICER Becker Joel was granted 45,880 shares, increasing direct ownership by 47% to 142,817 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-becker-joel-was-granted-45880-shares-increasing-6562854)
- 2026-05-15 20:35 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-neuropace-inc-6557998)
- 2026-05-12 20:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neuropace Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neuropace-inc-6548641)
- 2026-05-12 20:07 UTC [SEC Form 8-K] [Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neuropace-inc-filed-sec-form-8-k-results-of-operations-and-6547989)
- 2026-05-12 20:05 UTC [Earnings Date] [NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance](https://www.quantisnow.com/insight/neuropace-reports-first-quarter-2026-financial-results-and-raises-2026-6547829)
- 2026-04-29 20:05 UTC [Earnings Date] [NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026](https://www.quantisnow.com/insight/neuropace-to-report-first-quarter-2026-financial-results-on-may-6521024)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NPCE
- Earnings history: https://www.quantisnow.com/earnings/NPCE
- Dividend history: https://www.quantisnow.com/dividends/NPCE
- Insider transactions: https://www.quantisnow.com/insiders/NPCE
- Options chain: https://www.quantisnow.com/options/NPCE
- SEC 8-K filings only: https://www.quantisnow.com/company/NPCE/8-k
- RSS and alerts for NPCE: https://www.quantisnow.com/docs/rss-feeds.md